- Patients aged at least 18 years, seen by the oncologist for chemotherapy for solid
- Patients for whom the oncologist has decided the initiation of G-CSF biosimilar
treatment (Nivestim®) in primary or secondary prophylaxis.
- Patients informed about the computer processing of their medical data and their right
of access and correction.
- Patients with contraindication of use of Nivestim®.
- Patients with haematological malignancy including Myelodysplasia and Chronic myeloid
leukemia treated or untreated.
- Patients participating or having participated in the previous month in a clinical
- Patients refusing to participate in this study.